Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 2
2011 1
2013 4
2014 2
2015 1
2016 3
2018 2
2019 1
2021 1
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Formulated Phospholipids as Non-Canonical TLR4 Agonists.
Liang H, Lykins WR, Seydoux E, Guderian JA, Phan T, Fox CB, Orr MT. Liang H, et al. Among authors: guderian ja. Pharmaceutics. 2022 Nov 22;14(12):2557. doi: 10.3390/pharmaceutics14122557. Pharmaceutics. 2022. PMID: 36559051 Free PMC article.
Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy.
Abhyankar MM, Orr MT, Kinsey R, Sivananthan S, Nafziger AJ, Oakland DN, Young MK, Farr L, Uddin MJ, Leslie JL, Burgess SL, Liang H, De Lima I, Larson E, Guderian JA, Lin S, Kahn A, Ghosh P, Reed S, Tomai MA, Pedersen K, Petri WA Jr, Fox CB. Abhyankar MM, et al. Among authors: guderian ja. Front Immunol. 2021 Jun 25;12:683157. doi: 10.3389/fimmu.2021.683157. eCollection 2021. Front Immunol. 2021. PMID: 34248966 Free PMC article.
A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies.
Takashima E, Nagaoka H, Correia R, Alves PM, Roldão A, Christensen D, Guderian JA, Fukushima A, Viebig NK, Depraetere H, Tsuboi T. Takashima E, et al. Among authors: guderian ja. Front Immunol. 2022 Oct 27;13:1002430. doi: 10.3389/fimmu.2022.1002430. eCollection 2022. Front Immunol. 2022. PMID: 36389677 Free PMC article.
A structure-function approach to optimizing TLR4 ligands for human vaccines.
Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG. Carter D, et al. Among authors: guderian ja. Clin Transl Immunology. 2016 Nov 2;5(11):e108. doi: 10.1038/cti.2016.63. eCollection 2016 Nov. Clin Transl Immunology. 2016. PMID: 27990284 Free PMC article.
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.
El Bissati K, Chentoufi AA, Krishack PA, Zhou Y, Woods S, Dubey JP, Vang L, Lykins J, Broderick KE, Mui E, Suzuki Y, Sa Q, Bi S, Cardona N, Verma SK, Fraczek L, Reardon CA, Sidney J, Alexander J, Sette A, Vedvick T, Fox C, Guderian JA, Reed S, Roberts CW, McLeod R. El Bissati K, et al. Among authors: guderian ja. JCI Insight. 2016 Sep 22;1(15):e85955. doi: 10.1172/jci.insight.85955. JCI Insight. 2016. PMID: 27699241 Free PMC article.
Intranasal delivery of a synthetic Entamoeba histolytica vaccine containing adjuvant (LecA + GLA-3 M-052 liposomes): In vitro characterization.
Murphy BM, Chen JZ, Rolo M, Eldam M, Jordan L, Sivananthan SJ, Kinsey R, Guderian JA, Pedersen K, Abhyankar M, Petri WA, Fox CB, Finlay WH, Vehring R, Martin AR. Murphy BM, et al. Among authors: guderian ja. Int J Pharm. 2022 Oct 15;626:122141. doi: 10.1016/j.ijpharm.2022.122141. Epub 2022 Sep 2. Int J Pharm. 2022. PMID: 36058408
Lyophilization Process Engineering and Thermostability of ID93 + GLA-SE, a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies.
Dutill TS, Archer MC, McCollum J, Press C, McNeill L, Hawkins L, Phan T, Laursen E, Cabullos R, Bouchard L, Castro RJ, Lin MW, Roco J, Blois C, Adeagbo B, Guderian JA, Gerhardt A, Beckmann AM, Trappler EH, Kramer RM, Fox CB. Dutill TS, et al. Among authors: guderian ja. Front Drug Deliv. 2022;2:1043756. doi: 10.3389/fddev.2022.1043756. Epub 2022 Nov 8. Front Drug Deliv. 2022. PMID: 37771324 Free PMC article.
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.
Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, O'Donnell J, Pattabhi S, Guderian JA, Mohamath R, Duthie MS, Reed SG. Raman VS, et al. Among authors: guderian ja. J Immunol. 2010 Aug 1;185(3):1701-10. doi: 10.4049/jimmunol.1000238. Epub 2010 Jul 2. J Immunol. 2010. PMID: 20601594 Free PMC article.
A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7.
Fox CB, Sivananthan SJ, Duthie MS, Vergara J, Guderian JA, Moon E, Coblentz D, Reed SG, Carter D. Fox CB, et al. Among authors: guderian ja. J Nanobiotechnology. 2014 Apr 26;12:17. doi: 10.1186/1477-3155-12-17. J Nanobiotechnology. 2014. PMID: 24766820 Free PMC article.
Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions.
Fisher KJ, Kinsey R, Mohamath R, Phan T, Liang H, Orr MT, Lykins WR, Guderian JA, Bakken J, Argilla D, Ramer-Denisoff G, Larson E, Qi Y, Sivananthan S, Smolyar K, Carter D, Paddon CJ, Fox CB. Fisher KJ, et al. Among authors: guderian ja. NPJ Vaccines. 2023 Feb 16;8(1):14. doi: 10.1038/s41541-023-00608-y. NPJ Vaccines. 2023. PMID: 36797262 Free PMC article.
22 results